Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers

被引:1
|
作者
Picton, Anabela C. P. [1 ]
Paximadis, Maria [1 ,2 ]
Koor, Gemma W. [1 ,2 ]
Bharuthram, Avani [1 ,2 ]
Shalekoff, Sharon [1 ,2 ]
Lassauniere, Ria [3 ]
Ive, Prudence [2 ,4 ]
Tiemessen, Caroline T. [1 ,2 ]
机构
[1] Natl Inst Communicable Dis, Ctr HIV & STIs, Johannesburg, South Africa
[2] Univ Witwatersrand, Sch Pathol, Dept Virol, Fac Hlth Sci, Johannesburg, South Africa
[3] Statens Serum Inst, Dept Virus & Microbiol Special Diagnost, Virus Res & Dev Lab, Copenhagen, Denmark
[4] Univ Witwatersrand, Sch Clin Med, Dept Internal Med, Clin HIV Res Unit, Johannesburg, South Africa
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
HIV-1; control; CCR5; expression; immune activation; ligands; IL-10; IMMUNODEFICIENCY-VIRUS TYPE-1; T-LYMPHOCYTE ACTIVATION; SERUM CHEMOKINE LEVELS; BETA-CHEMOKINES; DISEASE PROGRESSION; PLASMA-LEVELS; CELL SUBSETS; SOLUBLE CD14; INFECTION; SUSCEPTIBILITY;
D O I
10.3389/fimmu.2021.781263
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Unique Individuals who exhibit either suppressive HIV-1 control, or the ability to maintain low viral load set-points and preserve their CD4+ T cell counts for extended time periods in the absence of antiretroviral therapy, are broadly termed HIV-1 controllers. We assessed the extent to which black South African controllers (n=9), differ from uninfected healthy controls (HCs, n=22) in terms of lymphocyte and monocyte CCR5 expression (density and frequency of CCR5-expressing cells), immune activation as well as peripheral blood mononuclear cell (PBMC) mitogen-induced chemokine/cytokine production. In addition, relative CD4+ T cell CCR5 mRNA expression was assessed in a larger group of controllers (n=20) compared to HCs (n=10) and HIV-1 progressors (n=12). Despite controllers having significantly higher frequencies of activated CD4+ and CD8+ T cells (HLA-DR+) compared to HCs, CCR5 density was significantly lower in these T cell populations (P=0.039 and P=0.064, respectively). This lower CCR5 density was largely attributable to controllers with higher VLs (>400 RNA copies/ml). Significantly lower CD4+ T cell CCR5 density in controllers was maintained (P=0.036) when HCs (n=12) and controllers (n=9) were matched for age. CD4+ T cell CCR5 mRNA expression was significantly less in controllers compared to HCs (P=0.007) and progressors (P=0.002), whereas HCs and progressors were similar (P=0.223). The levels of soluble CD14 in plasma did not differ between controllers and HCs, suggesting no demonstrable monocyte activation. While controllers had lower monocyte CCR5 density compared to the HCs (P=0.02), significance was lost when groups were age-matched (P=0.804). However, when groups were matched for both CCR5 promoter haplotype and age (n=6 for both) reduced CCR5 density on monocytes in controllers relative to HCs was highly significant (P=0.009). Phytohemagglutinin-stimulated PBMCs from the controllers produced significantly less CCL3 (P=0.029), CCL4 (P=0.008) and IL-10 (P=0.028) compared to the HCs, which was largely attributable to the controllers with lower VLs (<400 RNA copies/ml). Our findings support a hypothesis of an inherent (genetic) predisposition to lower CCR5 expression in individuals who naturally control HIV-1, as has been suggested for Caucasian controllers, and thus, likely involves a mechanism shared between ethnically divergent population groups.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients
    Soulie, Cathia
    Malet, Isabelle
    Lambert-Niclot, Sidonie
    Tubiana, Roland
    Thevenin, Monique
    Simon, Anne
    Murphy, Robert
    Katlama, Christine
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    AIDS, 2008, 22 (16) : 2212 - 2214
  • [42] Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists
    Henrich, Timothy J.
    Lewine, Nicolas R. P.
    Lee, Sun-Hee
    Rao, Suhas S. P.
    Berro, Reem
    Gulick, Roy M.
    Moore, John P.
    Tsibris, Athe M. N.
    Kuritzkes, Daniel R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (04) : 1931 - 1935
  • [43] Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression
    Wahl, SM
    Greenwell-Wild, T
    Peng, G
    Hale-Donze, P
    Doherty, TM
    Mizel, D
    Orenstein, JM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (21) : 12574 - 12579
  • [44] Expression of CCR5, a chemokine receptor involved in human immunodeficiency virus (HIV-1) infection
    Loy, BA
    Guo, H
    Du, J
    Lear, SC
    Martin, AW
    Peiper, SC
    LABORATORY INVESTIGATION, 1997, 76 (01) : 817 - 817
  • [45] Vitamin E supplementation increases the expression of the CCR5 coreceptor in HIV-1 infected subjects
    PierrePortales
    Guerrier, T
    Clot, J
    Corbeau, P
    Mettling, C
    Lin, YL
    Baillat, V
    de Boever, CM
    Moing, VL
    Tramoni, C
    Reynes, J
    Segondy, M
    CLINICAL NUTRITION, 2004, 23 (05) : 1244 - 1245
  • [46] Sex differences in HIV-1 viral load due to sex difference in CCR5 expression
    Portales, P
    Clot, J
    Corbeau, P
    ANNALS OF INTERNAL MEDICINE, 2001, 134 (01) : 81 - 82
  • [47] Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES
    Nardese, V
    Longhi, R
    Polo, S
    Sironi, F
    Arcelloni, C
    Paroni, R
    DeSantis, C
    Sarmientos, P
    Rizzi, M
    Bolognesi, M
    Pavone, V
    Lusso, P
    NATURE STRUCTURAL BIOLOGY, 2001, 8 (07) : 611 - 615
  • [48] Circulating South African transmitted/founder HIV-1 subtype C uses CCR5 and not CXCR4 or CCR3 for cell entry
    Sojane, K.
    Gounder, K.
    Chopera, D.
    Dong, K.
    Ndung'u, T.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24
  • [49] Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc
    Latinovic, Olga
    Kuruppu, Janaki
    Davis, Charles
    Le, Nhut
    Heredia, Alonso
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1497 - 1510
  • [50] Interaction of small molecule inhibitors of HIV-1 entry with CCR5
    Seibert, Christoph
    Ying, Weiwen
    Gavrilov, Svetlana
    Tsamis, Fotini
    Kuhmann, Shawn E.
    Palani, Anandan
    Tagat, Jayaram R.
    Clader, John W.
    McCombie, Stuart W.
    Baroudy, Bahige M.
    Smith, Steven O.
    Dragic, Tatjana
    Moore, John P.
    Sakmar, Thomas P.
    VIROLOGY, 2006, 349 (01) : 41 - 54